Neurobehavioral Manifestations
40 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| ACP-204 for hallucinations | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acupuncture for agnosia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aticaprant for anhedonia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Baclofen for psychomotor agitation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for aphasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for aphasia, broca | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for dysarthria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buprenorphine hydrochloride for agnosia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chronic speech BCI for speech disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for aphasia, primary progressive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depression Cognitive Training + tDCS (active stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depression Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Divalproex sodium for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab for down syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram oxalate for aphasia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram oxalate for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FLUOROETHOXYBENZOVESAMICOL F-18 for down syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IM ketamine in dose finding and then continuation for phantom limb | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketoprofen for agnosia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for language disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Levoleucovorin calcium for language disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lithium for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) for lethargy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MRI + Psilocybin + Risperidone for anhedonia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| N1 Implant + R1 Robot for dysarthria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Non-Specific Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for agnosia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for anhedonia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for memory disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| stimulation device for persistent vegetative state | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Suzetrigine for agnosia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| the Terumo Hydropearl® microspheres device for agnosia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vagus nerve stimulation; for persistent vegetative state | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valproic acid for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vasopressin for agnosia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |